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T
umors arise and progress in immu-
nocompetent hosts presumably by
activating tolerance mechanisms critical
for normal homeostasis. Host immune
cells can mount anti-tumor responses by
activation of Toll-like receptors (TLRs).
However, emerging data suggests that
molecules that negatively regulate TLRs
are exploited by tumors to induce
tolerance and mitigate the host immu-
nosurveillance. Targeting these negative
regulators can be a potential new immu-
notherapeutic strategy.
As an important extrinsic tumor suppressive
mechanism, immune system can identify
and destroy nascent tumor cells through
a process known as cancer immuno-
surveillance. However, tumors still arise
in immune-competent hosts, after pro-
gressing through three distinct phases of
a process known as immunoediting.
1 In
the first phase termed elimination, which
also encompasses immunosurveillance,
the innate and adaptive immune systems
work together to detect the presence of a
developing tumor and destroy it. Malignant
cell variants that survive the elimination
phase enter the equilibrium phase, in which
the adaptive immune system prevents
outgrowth of tumor and sculpts the
immunogenicity of the malignant cells.
During the escape phase, malignant cells
acquire the ability to circumvent immune
recognition and manifest into visible
tumors. Tumors do so by exploiting several
different tolerance mechanisms, which are
also employed by the host to maintain
the normal immune homeostasis.
1
Host immune cells can launch anti-
tumor responses through activation of cell
surface receptors, including toll-like recep-
tors (TLRs), which are capable of sensing
exogenous and endogenous danger signals.
To strike an immunological balance
between activation and inhibition and to
avoid triggering inappropriate inflam-
matory responses, the immune system
tightly regulates TLR signaling through
multiple negative regulatory mechanisms.
2
Molecules that negatively regulate TLR
signaling may be exploited by tumors to
induce immune tolerance and mitigate host
immunosurveillance. Recently, we demon-
strated that tumor cells induce the expres-
sion of IRAK-M, a negative regulator of
TLR signaling, in tumor associated macro-
phages, promoting an immunosuppressive
M2 phenotype. Tumor cell induced
IRAK-M is mediated by the cytokine
TGFβ, which serves as a key mechanism
by which lung tumors may circumvent
anti-tumor responses of macrophages pro-
moting tumor immunotolerance.
3 In this
article, we discuss the implications, poten-
tial role in immunoediting and prospects
for IRAK-M and other negative regulators
of TLR signaling for potential therapeutic
targeting in oncoimmunology.
TLR Signaling and Tolerance
for Tumors
Toll like receptors are critical components
of innate immunity and are broadly
distributed on cells of the immune system.
TLRs are evolutionarily conserved to
recognize molecular patterns associated
with pathogens (PAMPs) such as bacterial
lipopolysaccharides (LPS), hypomethyl-
ated DNA, flagellin, dsRNA. In addition,
molecular patterns associated with tissue
damage (danger associated molecular
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proteins, high mobility group box proteins
and dsDNA can directly activate TLRs.
4
TLR signaling is initiated by dimerization
of TLRs, forming homodimers or hetero-
dimers. All TLRs, with the exception of
TLR3, recruit and utilize the adaptor
protein MyD88 for signaling upon recep-
tor activation. This allows the recruitment
and activation of a family of kinases,
namely IRAKs (IL-1 receptor-associated
kinases) 1, 2 and 4. IRAK-4 is initially
recruited to the complex, becomes acti-
vated, and then phosphorylates IRAK-1.
These kinases interact with MyD88
through the death domains common to
both proteins, resulting in a cascade of
interactions culminating in the activation
of further downstream kinases, including
inhibitor of NFkB( I kB) kinases (IKKs).
Activation of IkB releases NFkB, allowing
NFkB translocation to the nucleus to
mediate an increase in inflammatory
cytokine gene expression.
4,5 The specificity
and diversity of TLR function is conferred
in part by the selective interaction with
the adaptor molecules. For example, the
adaptor MAL is vital for both TLR2 and
TLR4 activation of NFkB, whereas, TLR3
uses the adaptor TRIF to induce inter-
feron-β (IFNβ) synthesis and TLR4 uses
both TRIF and TRAM to activate the
IRF-3 signaling pathway.
5 There are other
signaling pathways that contribute to TLR
function, such as Jun N-terminal kinase
(JNK) and the mitogen-activated protein
kinases (MAPKs). The relationship and
interaction between these various signaling
pathways is a major subject of interest in
TLR biology.
In the tumor microenvironment, the
exact trigger(s) of TLR signaling in host
immune cells is not known. However, the
tumor microenvironment is rich in mole-
cules that can potentially activate TLR
signaling to trigger anti-tumor responses.
This includes heat shock proteins, high
mobility group proteins, double stranded
DNA from necrotic tumor cells, and
hyaluronic acid.
6,7 Tumors may activate
the same negative regulatory mechanisms
that are critical for normal homeostasis of
the immune system, and induce immune
tolerance to cancer cells. Dynamic inter-
actions between cancer cells and tumor
associated host immune cells initiate and
maintain tumor immune tolerance which
eventually predominates and overcomes
effective host immune response.
7,8 The
nature of the interactions between cancer
cells and immune cells, and the molecular
mechanisms underlying tumor-induced
immune tolerance is poorly understood.
Even though a number of molecules that
negatively regulate TLR signaling has been
identified and been shown to play an
important role in both limiting excessive
inflammation as well as immune tolerance,
their role in tumor immunology has just
started to emerge.
Negative Regulators
of TLR Signaling
Negative regulators of TLRs can selectively
inhibit one or more TLRs or target com-
mon components of the TLR-signaling
pathway that function to block the effects
of the entire TLR family (for a compre-
hensive review see ref. 2). The selective use
of negative regulators by different TLRs,
sometimes in a tissue specific manner,
might therefore contribute to the func-
tional specificity and diversity of TLR
responses. In order to attenuate signaling
events downstream of TLRs, at least three
levels of negative regulation have so
far been reported. These include extra-
cellular decoy receptors to intracellular
inhibitors, and membrane-bound suppres-
sors (Fig.1).
2 In addition, several miRNAs
have been identified as negative regulators
of TLR signaling.
9 However, functional
studies establishing their roles are lacking
and for that reason these molecules will
not be addressed in this article. Moreover,
while a number of TLR inhibitors
have been shown to promote a tolerance
phenotype in monocyte/macrophage
populations under certain experimental
conditions, only IRAK-M has been
directly linked to macrophage tolerance
within the tumor microenvironment.
Extracellular decoy receptors. There
are at least two soluble forms of TLRs
(sTLRs) identified so far. These naturally
produced decoy sTLRs may serve as first
line of negative regulation to prevent
overactivation of host response against
microbial threat. Even though TLR4
and TLR2 are encoded by single distinct
genes, multiple different mRNA products
are detected for each in various mam-
malian hosts, including humans, indicat-
ing the presence of different isoforms.
Recombinant form of sTLR4 inhibited
LPS-induced NFkB activation and TNFa
production by macrophages in vitro.
10
Similarly, sTLR2 isoforms, with molecular
weights from 20–85 kDa, were detected in
human milk and plasma, resulting from
the post-translational modification of
the transmembrane receptor.
11 Similarly,
sTLR2 inhibited IL-8 and TNFa pro-
duction by monocytes stimulated with
the TLR2 agonist, bacterial lipopeptide.
sTLR4 and sTLR2 may inhibit signaling
by blocking the interaction between TLR4
or TLR-2 and other co-receptors, particu-
larly MD2 and CD14 (Fig.1).
Intracellular inhibitors. Intracellular
molecules constitute the largest group of
negative regulators that inhibit TLR signal-
ing in both humans and mice. These
molecules include short form of MyD88
(MyD88s), TRIAD3A, A20, NOD2,
PI3K, SOCS1, TOLLIP, FADD, IRAK-
2c, IRAK-2d and IRAK-M (Fig.1).
Similar to the decoy sTLRs, an alter-
natively spliced MyD88s was identified
that acts as a dominant negative inhibitor
of MyD88. In contrast to the ubiquitous
MyD88 expression, MyD88s was pre-
dominantly expressed in spleen and
brain. MyD88s overexpression results in
MyD88s-MyD88heterodimers,ratherthan
MyD88-MyD88 homodimers required for
IRAK-4 recruitment. This prevents IRAK-1
phosphorylation by IRAK-4, resulting
in the inhibition of MyD88-dependent
signaling. Consequently, MyD88s inhibits
LPS and IL-1 induced NFkB activation
in vitro.
12,13
TRIAD3A is a member of E3-ubiquitin
ligases that promotes ubiquitylation
and degradation of TLR4 and 9 but not
TLR2. Overexpression of TRIAD3A
reduced LPS- and CpG-induced NFkB
activity, whereas knockdown of TRIAD3A
enhances TLR expression and increases
signaling in vitro.
14 Conversely, A20 is a
deubiquitylating enzyme that blocks both
MyD88-dependent and independent TLR
signaling by deubiquitylating TRAF6, a
common signaling component shared by
all TLRs.
15
NOD2 is an intracellular pathogen pat-
tern recognition receptor in the Nod-like
POINT-OF-VIEW
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muramyl dipeptide (MDP). Interestingly,
ligation of NOD2 has been shown to
specifically inhibit TLR2-mediated signal-
ing. NOD2-deficient mice demonstrated
enhanced TH1 responses when stimulated
with TLR2 ligands, but not other TLR
ligands.
16 PI3K, a ubiquitously expressed
signaling molecule that functions as an
early event in many cellular responses, was
also shown to inhibit TLR signaling.
Unlike NOD2, PI3K-deficient mice
show enhanced TH1 responses when
stimulated with several TLR agonists,
including TLR2, TLR4 and TLR9
ligands.
17 The mechanism(s) by which
NOD2 and PI3K inhibit TLR signaling
is not well defined, but both were shown
to suppress NFkB activation downstream
of TLR activation.
16,17
An additional group of intracellular
negative regulators are adaptor molecules
that target IRAK-1. One such molecule,
suppressor of cytokine signaling 1
(SOCS1), inhibits TLR4 and TLR9
signaling by suppressing IRAK-1 expres-
sion.
18 The Toll-interacting protein
(TOLLIP) inhibits autophosphorylation
of IRAK-1 to negatively regulate both
TLR2 and TLR4 signaling.
19 The death
receptor binding adaptor protein, FADD,
impairs IRAK-1 interaction with MyD88
to block TLR2 and TLR4 mediated
signaling in endothelial cells.
20 IRAK-2c
and IRAK-2d are the alternatively spliced
variants of IRAK-2 that lack death
domains and have been shown to inhibit
LPS-induced NFkB activation.
21 Lastly,
IRAK-M (also referred to as IRAK-3) is
the inactive kinase member of the IRAK
family, one of the first identified and
most studied negative regulators of TLR
signaling.
22 A more detailed discussion
on IRAK-M in the context of tumor
immunosuppression will be discussed
further.
Membrane-bound suppressors. Trans-
membrane proteins, such as ST2, SIGIRR,
TRAILR and CD11b constitute another
group of important negative regulators of
TLR signaling. ST2, and SIGIRR are the
two orphan receptors that block NFkB
activation in response to IL-1, TLR4 and
TLR9 ligands but not to TLR3 ago-
nists.
23,24 ST2 exists as two alternately
spliced transmembrane forms (ST2L)
expressed in hematopoietic cells, and a
soluble form (sST2) that is present in both
hematopoietic and non-hematopoietic
cells. ST2-deficient mice were no different
than wild-type mice in their response to
endotoxin-induced shock, but failed to
develop LPS tolerance.
23 This suggests that
ST2 may plays an important role in
regulating sustained TLR responses.
ST2L suppresses IL-1 and TLR signaling
Figure1. Negative regulation of Toll-like receptor signaling. Toll-like receptor (TLR) signaling pathways are tightly regulated in multiple different ways
by several endogenous regulators to prevent hyperactivation. To attenuate the signaling from TLRs, at least three levels of negative regulation have
so far been reported. These range from intracellular inhibitors to extracellular decoy receptors, and membrane-bound suppressors.
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through TIR domain. In addition, sST2
was shown to inhibit mRNA expression
of TLR4 and TLR1 in response to LPS.
SIGIRR is a transmembrane protein with
a extracellular domain that interfers with
TLR4, TLR5, and TLR9 ligand binding,
and a long non-signaling intracellular
domain that interfers with recruitment
of IRAK-1 and TRAF6. Interestingly,
SIGIRR is most highly expressed by
epithelial cells, including in kidney, gut,
and lung. SIGIRR deficient mice show
exaggerated response to TLR4 and TLR9
activation and enhanced susceptibility
to endotoxin shock.
24 Interestingly, mice
deficient in the membrane-bound negative
regulator, TRAILR, also showed enhanced
viral clearance and increased cytokine
production in response to TLR2, TLR3,
and TLR4 but not to TLR9.
25 Another
novel mechanism identified in macro-
phages is TLR-induced activation of
CD11b, which inhibits TLR signaling by
targeting MyD88 and TRIF for Cbl-b-
mediated proteolytic degradation (Fig.1).
Consistent with other negative regulators,
CD11b-deficient mice also show enhanced
inflammatory cytokines in circulation and
are susceptible to septic shock.
26
IRAK-M and Tumor-Induced
Tolerance
IRAK-M is an intracellular negative regu-
lator of TLR signaling and probably the
only molecule to date investigated in the
context of tumor immunology. It is an
inactive kinase that antagonizes TLR
signaling through protein-protein interac-
tions preventing activation of IRAK-1.
IRAK-M is regarded as a key negative
regulator of TLR signaling in macrophages
preventing excessive inflammatory res-
ponses.
22 Unfortunately, in pathologies
such as sepsis and cancer, immune sup-
pressive function of IRAK-M is exploited
to evade host immune surveillance.
Enhanced expression of IRAK-M was
observed in alveolar macrophages during
sepsis-induced immune suppression
27 and
in PBMCs isolated from patients with
chronic myeloid leukemia.
28
We have shown that tumor associated
macrophages (TAMs) express significantly
higher levels of IRAK-M compared with
the peritoneal macrophages (PEMs) from
the same tumor bearing mice. Sub-
cutaneous implantation of LLC cells in
IRAK-M null mice resulted in a five-fold
reduction in tumor growth, as compared
with tumors in wild type (WT) animals.
TAMs isolated from IRAK-M-deficient
mice displayed a classically-activated M1
phenotype rather than M2 phenotype
observed in TAMs from WT mice.
Human lung cancer cells induced
IRAK-M expression in human PBMCs
when co-cultured together. Tumor cell-
induced expression of IRAK-M was
TGFβ dependent.
3 However, the
mechanism by which TGFβ induced
IRAK-M expression is not known.
Bioinformatics analysis of human and
mouse IRAK-M promoter identified
Smad3 binding elements (unpublished
observations). Ongoing studies in our
lab will verify the direct binding of
Smad3 to IRAK-M promoter and its
functional significance in regulating
TGFβ-induced IRAK-M expression.
Importantly, enhanced IRAK-M expres-
sion in primary lung tumors correlated
with poor survival in patients with lung
cancer.
3 Collectively, our data demon-
strated that TGFβ-dependent induction
of IRAK-M expression is an important,
clinically relevant mechanism by which
tumors may circumvent anti-tumor
responses of macrophages. Recent studies
implicating a role for IRAK-M in regulat-
ing TLR responses in other cell types
raising the question as to whether
changes in macrophage phenotype in the
IRAK-M deficient mice is solely respons-
ible for inhibitory effects on tumor
growth. Studies are underway in our
laboratory to address this issue by using
bone marrow chimera mouse models. The
major deficiency in many of the earlier
studies, including ours, was use of existing
cell lines that are already immunoedited.
To gain precise insights into the role of
IRAK-M in the process of immunoediting,
it is necessary to investigate by using a
chemical or genetic model of carcino-
genesis in an immunocompetent host.
To this end we recently developed a
mouse model by crossing the inducible
K-ras mouse model of lung cancer into
IRAK-M-deficient background (unpub-
lished studies).
A Potential New Class
of Therapeutic Targets
for Oncoimmunology
To develop more effective immunothera-
pies, immunologists must identify the
cellular and molecular mechanisms that
either eliminate or promote cancer
development. For this reason, inhibitors
of TLR signaling may be therapeutically
useful in switching the nature of the tumor
microenvironment from one of tumor-
promoting inflammation to that of tumor-
eliminating immunity. Surprisingly, with
the exception of IRAK-M, the expression
or the role of other TLR negative
regulators has not been investigated in
the context of tumor immunology. In a
preliminary analysis, we assessed the
mRNA expression of some of the negative
regulators discussed above, in a spectrum
of human cancers using Oncomine data-
base (www.oncomine.com).
29 Interestingly,
five out of six molecules assessed showed
upregulation in the majority of unique
analyses comparing cancer cells vs.
normal tissue (Fig.2). For example, A20
was upregulated (within top 10% with
FC . 2 and p-value , 0.0001) in 17
unique analyses (sample sets) compared
with its downregulation in 8 (Fig.2).
This shows a trend toward increased
expression in tumors, where head and
neck cancers stand out with upregulation
in six unique analyses. This trend is con-
sistent with our recent finding that high
IRAK-M expression in tumors correlated
with poor survival in patients with lung
cancer.
3 By comparison, for NOD2
expression there was a reverse correlation
with two up and seven down. It should
be cautioned that the mRNA data in the
oncomine data sets is derived from entire
tumors, without any consideration or
separation for their immune component.
Therefore, it’s worth noting that these
correlations may not truly represent a
proof-of-principle but provides a rationale
and starting point for further investigation.
However, the lack-of or negative correla-
tion in this analysis does not preclude a
molecule from further investigation.
In light of emerging IRAK-M data, it’s
reasonable to expect an important role
for other negative regulators in conferr-
ing tumor tolerance. It is necessary to
www.landesbioscience.com OncoImmunology 343investigate the effect of each of these
molecules on immunoediting, starting
with molecules for which knockout
mouse models are currently available.
Given the TGFβ regulation of IRAK-M,
it is important to explore the regulation
of other negative regulators by TGFβ or
other immunosuppressive cytokines in
the tumor microenvironment. The tissue
or cell type-specific expression of some
regulators suggests that it would not be
surprising to see tumor type specific
mechanisms in operation. In summary,
understanding the functional control of
immune-suppressive networks, including
the role of TLR signaling and their nega-
tive regulators, may offer new opportun-
ities to shift the balance between tolerance
andimmunity.Theidentificationandtarget-
ing such nodes and molecules will facilitate
the elimination of tolerance phenomena
in the tumor microenvironment and aid
the development of effective cancer
immunotherapeutic strategies.
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